Recursion Venture Capital

The firm applies recursive, data-driven analytical frameworks — conceptually similar to those used in computational biology and drug discovery — to identify early-stage technology and life sciences startups. The thesis hinges on the belief that systematic pattern recognition across large, structured data sets can surface high-potential companies before they become visible in conventional venture pipelines. This approach prioritizes founders building defensible data assets and intellectual property moats.

While the firm does not publicly disclose its sourcing methodology, its architecture and name suggest a systematic, data-intensive approach rather than relying solely on network-driven deal flow. The multi-office presence in Seattle, Bellevue, San Francisco, and Palo Alto positions it to capture opportunities across two major technology ecosystems. The firm likely employs proprietary data pipelines and algorithmic screening tools to identify targets at the seed and Series A stages.

Based on its computational-discovery thesis and venture capital structure, Recursion likely focuses on seed and Series A investments — stages where data-driven pattern recognition can provide the greatest informational advantage over traditional, relationship-based sourcing. Later-stage deployment would be inconsistent with the firm's structural emphasis on early identification and recursive analysis.

The firm operates from four offices: Seattle and Bellevue in Washington state, and San Francisco and Palo Alto in California. This dual-hub footprint spans the Pacific Northwest technology corridor and Silicon Valley, giving the firm exposure to distinct talent pools in cloud infrastructure, artificial intelligence, biotechnology, and enterprise software.

No. Recursion Venture Capital has not publicly disclosed its assets under management, fund sizes, or total deployment figures. The firm maintains a low public profile, with no known regulatory filings or press releases that would provide verified AUM data.

The primary structural differentiator is its application of computational-biology frameworks to investment decision-making — a systematic, algorithmic approach to sourcing and evaluation that more closely resembles quantitative hedge fund operations than conventional venture capital. The firm's name, 'Recursion,' signals an iterative, self-reinforcing analytical process designed to industrialize early-stage discovery without sacrificing high-conviction portfolio construction.

The firm has not publicly identified its leadership team, investment committee members, or general partners through its website, LinkedIn, or other official channels. No named principals can be confirmed through primary sources as of the latest available records.